Information Provided By: 
Fly News Breaks for September 15, 2015
MYGN
Sep 15, 2015 | 07:54 EDT
UBS noted Myriad Genetics management laid out its latest five year plan at its investor meeting yesterday. The firm said they appreciate management's approach, but reserve caution and project minimal earnings growth through 2020. UBS cited the potential for the emergence of competitors and the length of time to diversify from newer tests, while noting the roughly 40% short interest in the stock. UBS reiterated its Sell rating and $30 price target on Myriad Genetics shares.
News For MYGN From the Last 2 Days
There are no results for your query MYGN
